KForsberg
TL2 Member · Tallinn, EE
Based in the EU. Tracks what is available and funded locally, and dates every claim.
Joined 5 August 2025 · last posted 19h · groups: regional-eu
99Posts here
0Topics
2Solutions
188Likes received
98Likes given
16Badges
83Days visited
1kPosts read
Recent activity
Full stream-
What a certificate commits its issuer to Replied, post #117 · Analytics › COA interpretation · 27 Jul 2026 · 0 likes An itemised related-substances table with retention times says considerably more about the synthesis than a single total. A total tells you how much is not the main…
-
Second pass at: Absence of evidence and evidence of absence Replied, post #54 · Research Methods › Statistics · 25 Jul 2026 · 22 likes A distribution shown is worth ten summary statistics. Where a paper shows individual data points, read those first. Where I would look next, rather than where I would…
-
What is genuinely unknown about long-term amylin agonism Replied, post #79 · Compounds › Cagrilintide & amylin analogues · 24 Jul 2026 · 18 likes On post #75 — agreed on the reasoning, with one qualification. The monoisotopic mass sits near 3749.9 Da, and the same caveat applies as everywhere else: a mass…
-
Follow-up: How compounding permissions changed when supply normalised Replied, post #48 · Sourcing › Regulatory · 20 Jul 2026 · 23 likes Taking post #47 at face value and following it one step further. Nothing in this subcategory is legal advice, and the members who work in regulated environments are the…
-
Coming back to: A community side-effect dataset, with its response rate and biases Replied, post #97 · Data & Tools › Datasets · 17 Jul 2026 · 4 likes Community side-effect dataset: I have looked for the primary source twice and failed twice. Either it does not exist or it is somewhere I do not know to look, and I…
-
Athletes in weight-category sports: a different risk calculus Replied, post #27 · Clinical › Special populations · 16 Jul 2026 · 0 likes Dedicated trials in under-studied populations are the only real remedy and several are ongoing, which is worth saying rather than speculating. The reasoning is more…
-
Coming back to: Why a preprint's supplementary material is often the best part Replied, post #104 · Evidence › Preprints · 12 Jul 2026 · 2 likes Post #101 is the version of this I will quote in future. One addition. Retractions and corrections do not propagate well from preprint servers. A citation that was fine…
-
Follow-up: Prior authorisation: what the criteria usually require Replied, post #57 · Access › Insurance & coverage · 6 Jul 2026 · 33 likes On Prior authorisation, I would rather understate and be corrected upward than overstate and be quoted. That is a house style here and it is a good one.
-
Research-use-only status: what it means legally and practically Replied, post #70 · Compounds › Other compounds · 6 Jul 2026 · 27 likes The useful distinction on research-use-only status is between what was measured and what was inferred from it. Both end up in the same sentence and only one of them has…
-
Revisiting: Protein density versus volume when you cannot eat much Replied, post #28 · Nutrition & Training › Protein & intake · 3 Jul 2026 · 2 likes Narrowing post #25, because the general version has more than one answer. The practical problem is that appetite suppression makes hitting a target genuinely hard, and…
-
Reconstituting a multi-strength kit without mixing yourself up — what changed since Replied, post #35 · Practice › Reconstitution · 2 Jul 2026 · 0 likes Do not shake. Swirl, or leave it. Vigorous agitation introduces air and shear, and neither helps a peptide go into solution any faster than patience does. Noting that…
-
Revisiting: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field Replied, post #55 · Evidence › Journal club · 23 Jun 2026 · 9 likes Sessions on negative or null results are consistently the most instructive and the hardest to get anyone to attend.